Subscribe

Koninklijke Philips N.V. (PHIA.AS)

EUR23.36 -0.73 (-3.03%)
NL AMS Healthcare Medical - Devices
Address Philips Center 1096 BC
Amsterdam, NL
CEO Roy W. O. Jakobs
Website philips.com
IPO 1995-03-27
ISIN NL0000009538

Explore sections of this company profile

Also trades on Deutsche Börse · PHI1.DE (EUR) Deutsche Börse · PHIA.DE (EUR) Euronext Amsterdam · PHIA.AS (EUR) New York Stock Exchange · PHG (USD) Other OTC · RYLPF (USD)
Description

Koninklijke Philips N.V. operates as a leading global healthcare technology enterprise with a presence across North America and numerous international markets. Its operations are organized into three primary divisions: Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses. Within the Diagnosis & Treatment segment, Philips offers advanced diagnostic imaging technologies, including magnetic resonance (MRI), computed tomography (CT), X-ray systems, and innovative detector-based spectral CT solutions, alongside molecular and hybrid imaging for nuclear medicine. The company also provides integrated interventional systems and comprehensive echography (ultrasound) solutions, crucial for diagnosis, treatment planning, and guidance in areas like cardiology, general imaging, obstetrics/gynecology, and point-of-care settings. This segment is further supported by proprietary software platforms designed to facilitate diagnostics and interventions, as well as enterprise diagnostic informatics products and related services. The Connected Care division focuses on solutions for critical patient management, emergency response, and sleep and respiratory conditions. Additionally, it delivers electronic medical record (EMR) and broader care management platforms. For Personal Health, Philips provides a range of consumer products, encompassing oral hygiene solutions such as electric toothbrushes, brush heads, and interdental cleaning and teeth whitening systems. This segment also includes infant feeding and digital parenting solutions, along with male grooming and beauty devices. Philips actively pursues strategic collaborations to enhance its offerings, notably partnering with Ibex Medical Analytics Ltd. to jointly promote digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide. The company also maintains a strategic partnership agreement with NICO.LAB. Established in 1891 and headquartered in Amsterdam, the Netherlands, the company adopted its current name, Koninklijke Philips N.V., in May 2013, having previously operated as Koninklijke Philips Electronics N.V.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR23.36 -0.73 (-3.03%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.93
Float Shares
770.57M
Free Float %
81.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-3.40% -4.74% -8.82% -16.96% -12.91% -4.78% +0.73% +21.33% -47.20% +6.24% +13.37%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (22 ratings, all time) Hold
Price Targets & DCF
Current price
23.36
DCF (Unlevered) 48.81 +108.9%
DCF (Levered) 10.26 -56.1%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 45% Bullish
Rating 2026-05 Change
Strong Buy 5 0
Buy 4 0
Hold 11 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
1.96
Grey zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Devices: +11.2%
    -1.0% Q1'26: -4.7% (vs Q1'25)
  • ✓
    EPS growth Medical - Devices: +28.5%
    +224.0% ★ Q1'26: +97.5% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Devices: +30.9%
    +4.2% Q1'26: +2.9% (vs Q1'25)
  • ✗
    EBIT margin Medical - Devices: +6.2%
    +9.2% ★ Q1'26: +5.4% (vs Q1'25)
  • ✗
    ROIC Medical - Devices: +3.3%
    +7.7% ★ Q1'26: +3.8% (vs Q1'25)
  • ✗
    Share dilution Medical - Devices: 0.0%
    +3.1% Q1'26: +3.2% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×
    2.92× Q1'26: 4.27× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.92) × ERP
WACC = 74% × Ke + 26% × Kd (4.3%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 48.39 Current price: 23.36
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2011
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
18 Rev. Ana.
12 EPS Ana. 		Dec 2027
17 Rev. Ana.
11 EPS Ana. 		Dec 2028
15 Rev. Ana.
8 EPS Ana. 		Dec 2029
11 Rev. Ana.
6 EPS Ana. 		Dec 2030
7 Rev. Ana.
6 EPS Ana.
Revenue
22.58B
est: 22.92B (-1.5%)
24.79B
est: 25.17B (-1.5%)
23.33B
est: 23.74B (-1.8%)
21.39B
est: 23.01B (-7.0%)
24.24B
est: 24.17B (+0.3%)
24.52B
est: 24.59B (-0.3%)
17.78B
est: 17.98B (-1.1%)
18.12B
est: 18.10B (+0.1%)
19.48B
est: 19.56B (-0.4%)
19.54B
est: 19.53B (+0.0%)
17.16B
est: 17.29B (-0.8%)
17.83B
est: 17.42B (+2.3%)
18.17B
est: 18.13B (+0.2%)
18.02B
est: 18.15B (-0.7%)
17.83B
est: 17.73B (+0.6%)
17.86B
17.58B – 19.22B
+0.7% YoY
18.66B
18.27B – 20.16B
+4.5% YoY
19.48B
19.45B – 19.52B
+4.4% YoY
20.33B
19.96B – 21.92B
+4.4% YoY
21.13B
20.74B – 22.78B
+3.9% YoY
EBITDA
1.03B
est: 2.93B (-64.7%)
1.94B
est: 310.78M (+524.2%)
2.98B
est: 1.63B (+82.8%)
1.62B
est: 2.56B (-36.7%)
2.21B
est: 1.39B (+59.0%)
2.47B
est: 1.55B (+59.6%)
2.61B
est: 1.70B (+53.0%)
2.64B
est: 2.95B (-10.6%)
2.69B
est: 2.38B (+12.9%)
2.56B
est: 2.87B (-11.1%)
1.73B
est: 3.02B (-42.6%)
-280.00M
est: 3.13B (-108.9%)
1.04B
est: 4.61B (-77.4%)
1.85B
est: 4.65B (-60.2%)
2.77B
est: 4.51B (-38.5%)
4.54B
4.47B – 4.89B
+0.7% YoY
4.75B
4.65B – 5.13B
+4.5% YoY
4.96B
4.95B – 4.96B
+4.4% YoY
5.17B
5.08B – 5.58B
+4.4% YoY
5.37B
5.27B – 5.79B
+3.9% YoY
EBIT
-366.00M
est: 1.82B (-120.1%)
698.00M
est: -295.41M (+336.3%)
1.93B
est: 971.78M (+98.1%)
600.00M
est: 1.91B (-68.6%)
926.00M
est: 512.54M (+80.7%)
1.38B
est: 625.25M (+120.2%)
1.62B
est: 1.05B (+54.7%)
1.68B
est: 1.54B (+9.6%)
1.72B
est: 1.85B (-7.2%)
1.39B
est: 1.66B (-16.5%)
679.00M
est: 1.75B (-61.2%)
-1.48B
est: 1.81B (-181.6%)
-220.00M
est: 3.38B (-106.5%)
460.00M
est: 3.41B (-86.5%)
1.65B
est: 3.31B (-50.2%)
3.33B
3.28B – 3.58B
+0.7% YoY
3.48B
3.41B – 3.76B
+4.5% YoY
3.63B
3.63B – 3.64B
+4.4% YoY
3.79B
3.72B – 4.09B
+4.4% YoY
3.94B
3.87B – 4.25B
+3.9% YoY
Net Income
-1.30B
est: 1.28B (-201.5%)
226.00M
est: -1.42B (+115.9%)
1.17B
est: 213.23M (+448.2%)
415.00M
est: 1.13B (-63.2%)
645.00M
est: 437.66M (+47.4%)
1.45B
est: 638.53M (+126.8%)
1.66B
est: 1.05B (+57.2%)
1.09B
est: 1.68B (-35.1%)
1.17B
est: 1.17B (-0.3%)
1.19B
est: 1.18B (+0.4%)
3.32B
est: 1.24B (+167.1%)
-1.61B
est: 1.29B (-224.8%)
-466.00M
est: -605.01M (+23.0%)
-702.00M
est: 1.40B (-150.1%)
896.00M
est: 1.43B (-37.2%)
1.43B
1.31B – 1.55B
+0.4% YoY
1.61B
1.47B – 1.76B
+12.6% YoY
1.88B
1.73B – 2.02B
+16.3% YoY
1.98B
1.93B – 2.18B
+5.3% YoY
2.15B
2.10B – 2.37B
+8.7% YoY
SGA
6.00B
est: 5.28B (+13.7%)
6.27B
est: 6.59B (-4.9%)
6.02B
est: 5.91B (+1.9%)
5.87B
est: 5.81B (+1.0%)
7.02B
est: 6.19B (+13.4%)
6.73B
est: 5.16B (+30.5%)
4.98B
est: 3.49B (+42.4%)
5.13B
est: 4.86B (+5.6%)
5.31B
est: 5.35B (-0.8%)
5.27B
est: 5.17B (+1.9%)
4.86B
est: 5.44B (-10.7%)
5.28B
est: 5.64B (-6.4%)
5.13B
est: 5.16B (-0.5%)
5.07B
est: 6.23B (-18.7%)
4.97B
est: 5.04B (-1.4%)
5.08B
5.00B – 5.46B
+0.7% YoY
5.31B
5.19B – 5.73B
+4.5% YoY
5.54B
5.53B – 5.55B
+4.4% YoY
5.78B
5.67B – 6.23B
+4.4% YoY
6.01B
5.90B – 6.48B
+3.9% YoY
EPS
-1.28
est: 1.02 (-225.0%)
-0.04
est: 1.16 (-103.2%)
1.20
est: 1.56 (-23.1%)
0.42
est: 1.33 (-68.4%)
0.64
est: 1.25 (-48.9%)
1.48
est: 1.38 (+6.9%)
1.67
est: 1.33 (+25.1%)
1.11
est: 1.36 (-18.6%)
1.21
est: 1.67 (-27.6%)
1.21
est: 1.75 (-31.0%)
3.40
est: 1.63 (+108.2%)
-1.76
est: 0.74 (-339.2%)
-0.47
est: -0.61 (+22.3%)
-0.75
est: 1.40 (-153.5%)
0.94
est: 1.43 (-34.2%)
1.54
1.36 – 1.61
+7.6% YoY
1.71
1.53 – 1.83
+11.5% YoY
1.91
1.80 – 2.10
+11.5% YoY
2.05
2.01 – 2.26
+7.6% YoY
2.23
2.18 – 2.46
+8.7% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-07 B 3/5 3/5 3/5 4/5 1/5 2/5 3/5
2026-05-06 B 3/5 3/5 3/5 4/5 1/5 2/5 3/5
2026-05-05 B 3/5 3/5 3/5 4/5 1/5 2/5 3/5
2026-05-04 B 3/5 3/5 3/5 4/5 1/5 2/5 3/5
2026-04-30 B 3/5 3/5 3/5 4/5 1/5 2/5 3/5
2026-04-29 B 3/5 3/5 3/5 4/5 1/5 3/5 3/5
2026-04-28 B 3/5 3/5 3/5 4/5 1/5 3/5 3/5
2026-04-27 B 3/5 3/5 3/5 4/5 1/5 3/5 3/5
2026-04-24 B 3/5 3/5 3/5 4/5 1/5 2/5 3/5
2026-04-23 B 3/5 3/5 3/5 5/5 1/5 2/5 3/5
2026-04-22 B 3/5 3/5 3/5 5/5 1/5 2/5 3/5
2026-04-21 B 3/5 3/5 3/5 5/5 1/5 2/5 3/5
2026-04-20 B 3/5 3/5 3/5 5/5 1/5 2/5 3/5
2026-04-17 B 3/5 3/5 3/5 5/5 1/5 2/5 3/5
2026-04-16 B 3/5 3/5 3/5 5/5 1/5 2/5 3/5
2026-04-15 B 3/5 3/5 3/5 5/5 1/5 2/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
1.86B
OE per share TTM
1.93
Owner's Yield
8.34%
Maintenance CapEx ratio
66.26%
Maint CapEx / Avg PPE
14.1%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
24.5K
Shares Outstanding
951.29M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Roy Jakobs President, Chief Executive Officer & Chairman of the Board of Management 3M male
Charlotte Hanneman Executive Vice President, Chief Financial Officer & Member of Board of Management 2M female
Marnix J. van Ginneken Executive Vice President, Chief ESG & Legal Officer and Member of the Board of Management 2M male
Paulus A. Stoffels Independent Vice Chairman of Supervisory Board & Secretary 185.5K —
Jan Kimpen Chief Medical Officer — —
Heidi Sichien Executive Vice President & Chief People Officer — female
Henk Siebren de Jong Executive Vice President & Chief Executive Officer of Domestic Appliances — male
Pim Preesman Country Leader/ Health Systems Leader Indonesia — male
Durga Doraisamy Head of Investor Relations — female
Willem Appelo Executive Vice President & Chief Operating Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Devices